CA3183770A1 - Compounds having anticancer activity - Google Patents
Compounds having anticancer activityInfo
- Publication number
- CA3183770A1 CA3183770A1 CA3183770A CA3183770A CA3183770A1 CA 3183770 A1 CA3183770 A1 CA 3183770A1 CA 3183770 A CA3183770 A CA 3183770A CA 3183770 A CA3183770 A CA 3183770A CA 3183770 A1 CA3183770 A1 CA 3183770A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- alkyl
- heteroaryl
- compound
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047612P | 2020-07-02 | 2020-07-02 | |
| US63/047,612 | 2020-07-02 | ||
| PCT/US2021/040171 WO2022006447A1 (en) | 2020-07-02 | 2021-07-01 | Compounds having anticancer activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3183770A1 true CA3183770A1 (en) | 2022-01-06 |
Family
ID=79314944
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3183770A Pending CA3183770A1 (en) | 2020-07-02 | 2021-07-01 | Compounds having anticancer activity |
| CA3183776A Pending CA3183776A1 (en) | 2020-07-02 | 2021-07-01 | Compounds having antibacterial activity |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3183776A Pending CA3183776A1 (en) | 2020-07-02 | 2021-07-01 | Compounds having antibacterial activity |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20230295164A1 (enExample) |
| EP (2) | EP4175953A4 (enExample) |
| JP (2) | JP2023532128A (enExample) |
| CN (2) | CN115867354B (enExample) |
| AU (2) | AU2021301264A1 (enExample) |
| CA (2) | CA3183770A1 (enExample) |
| WO (2) | WO2022006447A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024531898A (ja) * | 2021-08-17 | 2024-09-03 | サウスウエスト リサーチ インスティテュート | コロナウイルスに対する阻害剤 |
| US20260138981A1 (en) * | 2022-10-07 | 2026-05-21 | The Trustees Of Princeton University | Dihydrofolate reductase inhibitors for anti-biotic resistant infections |
| CN118047780A (zh) * | 2022-11-09 | 2024-05-17 | 中国医学科学院药物研究所 | 一类喹唑啉杂环化合物及其抗感染和抗肿瘤的应用 |
| CN119661535B (zh) * | 2023-09-21 | 2026-03-20 | 中国医学科学院药物研究所 | 7H-吡咯并[3,2-f]喹唑啉衍生物及其抗感染应用 |
| WO2025195460A1 (zh) * | 2024-03-22 | 2025-09-25 | 深圳湾实验室坪山生物医药研发转化中心 | 稠环衍生物 |
| CN121013722A (zh) * | 2024-03-22 | 2025-11-25 | 深圳湾实验室坪山生物医药研发转化中心 | 结核病的预防与治疗 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE45427B1 (en) * | 1976-07-09 | 1982-08-25 | American Home Prod | Pyrrold 3,2if quinazoline-1,3-diamine and related compounds |
| US4118561A (en) * | 1977-04-06 | 1978-10-03 | American Home Products Corporation | 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines |
| JP2005500253A (ja) * | 2001-02-23 | 2005-01-06 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物 |
| US7253177B2 (en) * | 2004-10-22 | 2007-08-07 | United States Of America As Represented By The Secretary Of The Army | Synthesis and antimalarial activity of pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives |
| US9920058B2 (en) * | 2013-05-06 | 2018-03-20 | Georgia Tech Research Corporation | Molecules with potent DHFR binding affinity and antibacterial activity |
| WO2014205272A1 (en) * | 2013-06-20 | 2014-12-24 | Oregon Health & Science University | Pyrroloquinazoline compounds |
| EP3143036B1 (en) * | 2014-05-11 | 2023-08-02 | Tel Hashomer Medical Research Infrastructure and Services Ltd. | Par-1 based therapeutic conjugates and uses thereof |
| US11077109B2 (en) * | 2017-08-01 | 2021-08-03 | The Trustees Of Princeton University | Compounds having antibacterial activity and methods of use |
| US20210161900A1 (en) * | 2018-04-30 | 2021-06-03 | Duke University | Compositions and methods for the treatment of senescent tumor cells |
| WO2021035045A1 (en) * | 2019-08-20 | 2021-02-25 | City Of Hope | Mettl16 inhibitors and uses thereof |
-
2021
- 2021-07-01 CN CN202180047260.2A patent/CN115867354B/zh active Active
- 2021-07-01 JP JP2022581398A patent/JP2023532128A/ja active Pending
- 2021-07-01 CA CA3183770A patent/CA3183770A1/en active Pending
- 2021-07-01 WO PCT/US2021/040171 patent/WO2022006447A1/en not_active Ceased
- 2021-07-01 EP EP21832744.3A patent/EP4175953A4/en active Pending
- 2021-07-01 JP JP2023524493A patent/JP2023535527A/ja active Pending
- 2021-07-01 US US18/014,032 patent/US20230295164A1/en active Pending
- 2021-07-01 WO PCT/US2021/040143 patent/WO2022006432A1/en not_active Ceased
- 2021-07-01 CA CA3183776A patent/CA3183776A1/en active Pending
- 2021-07-01 US US18/013,302 patent/US20230242540A1/en active Pending
- 2021-07-01 EP EP21832527.2A patent/EP4175958A4/en active Pending
- 2021-07-01 CN CN202180047426.0A patent/CN116234808B/zh active Active
- 2021-07-01 AU AU2021301264A patent/AU2021301264A1/en active Pending
- 2021-07-01 AU AU2021299504A patent/AU2021299504A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021301264A1 (en) | 2023-02-02 |
| JP2023532128A (ja) | 2023-07-26 |
| AU2021299504A1 (en) | 2023-02-02 |
| US20230295164A1 (en) | 2023-09-21 |
| EP4175953A4 (en) | 2024-08-14 |
| US20230242540A1 (en) | 2023-08-03 |
| CA3183776A1 (en) | 2022-01-06 |
| WO2022006432A1 (en) | 2022-01-06 |
| CN115867354B (zh) | 2025-08-26 |
| WO2022006447A1 (en) | 2022-01-06 |
| JP2023535527A (ja) | 2023-08-17 |
| CN116234808B (zh) | 2025-11-14 |
| CN115867354A (zh) | 2023-03-28 |
| CN116234808A (zh) | 2023-06-06 |
| EP4175953A1 (en) | 2023-05-10 |
| EP4175958A4 (en) | 2024-07-17 |
| EP4175958A1 (en) | 2023-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115867354B (zh) | 具有抗癌活性的化合物 | |
| KR102908167B1 (ko) | 프로그램가능한 중합체성 약물 | |
| CN116457344B (zh) | 低分子量蛋白质降解剂及其应用 | |
| ES2824814T3 (es) | Compuestos farmacéuticos | |
| EP3567035B1 (en) | N-substituted 2,5-dioxo-azoline compounds for use in the treatment of cancer | |
| KR102831570B1 (ko) | 암 줄기 세포를 표적화하는 암 치료 | |
| KR20200037876A (ko) | Egfr 및/또는 her2의 저해제 및 사용 방법 | |
| CA3019450A1 (en) | Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application | |
| JP6615207B2 (ja) | 複素環式化合物及びその使用 | |
| EP3825310A1 (en) | Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies | |
| WO2008030373A2 (en) | L- oddc prodrugs for cancer | |
| CN116178456A (zh) | 用于克服铂耐受性的德克萨卟啉-pt(iv)缀合物及组合物 | |
| WO2016130271A1 (en) | Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors | |
| US20080176923A1 (en) | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | |
| BR112020014421A2 (pt) | compostos de alquinileno substituídos como agentes anticâncer | |
| WO2023217093A1 (en) | Prodrug activation of n-oxides by radiotherapy | |
| US20060264439A1 (en) | Inhibitors of polo-like kinase-1 | |
| JP2002535338A (ja) | ビス−テルピリジン−白金（ｉｉ）錯体 | |
| Barclay et al. | Synthesis of and Tumor Inhibition by a Tryptophan Mustard | |
| WO2019148244A1 (en) | Anti-cancer compounds | |
| RU2089507C1 (ru) | Комплексные соединения железа - ферроценилалкилполифторазолы, обладающие противоопухолевой активностью | |
| JP2011512387A (ja) | 銅有機複合体、抗腫瘍薬として及び健全な組織を電離放射線から保護するためのその使用 | |
| CN119823027A (zh) | 哌啶基哌啶修饰的β-咔啉开环化合物及其制备方法与应用 | |
| AU2024290511A1 (en) | Mitochondria specific transcription inhibitor compounds | |
| CN118619877A (zh) | 草酰二胺衍生物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250616 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250616 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250618 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250707 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250707 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250825 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250825 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250826 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20250912 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251218 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260708 |